Literature DB >> 22383685

ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma.

Wijtske Annema1, Arne Dikkers2, Jan Freark de Boer2, Thomas Gautier3, Patrick C N Rensen4, Daniel J Rader5, Uwe J F Tietge6.   

Abstract

ApoE plays an important role in lipoprotein metabolism. This study investigated the effects of adenovirus-mediated human apoE overexpression (AdhApoE3) on sterol metabolism and in vivo reverse cholesterol transport (RCT). In wild-type mice, AdhApoE3 resulted in decreased HDL cholesterol levels and a shift toward larger HDL in plasma, whereas hepatic cholesterol content increased (P < 0.05). These effects were dependent on scavenger receptor class B type I (SR-BI) as confirmed using SR-BI-deficient mice. Kinetic studies demonstrated increased plasma HDL cholesteryl ester catabolic rates (P < 0.05) and higher hepatic selective uptake of HDL cholesteryl esters in AdhApoE3-injected wild-type mice (P < 0.01). However, biliary and fecal sterol output as well as in vivo macrophage-to-feces RCT studied with (3)H-cholesterol-loaded mouse macrophage foam cells remained unchanged upon human apoE overexpression. Similar results were obtained using hApoE3 overexpression in human CETP transgenic mice. However, blocking ABCA1-mediated cholesterol efflux from hepatocytes in AdhApoE3-injected mice using probucol increased biliary cholesterol secretion (P < 0.05), fecal neutral sterol excretion (P < 0.05), and in vivo RCT (P < 0.01), specifically within neutral sterols. These combined data demonstrate that systemic apoE overexpression increases i) SR-BI-mediated selective uptake into the liver and ii) ABCA1-mediated efflux of RCT-relevant cholesterol from hepatocytes back to the plasma compartment, thereby resulting in unchanged fecal mass sterol excretion and overall in vivo RCT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22383685      PMCID: PMC3329392          DOI: 10.1194/jlr.M020743

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  48 in total

1.  Endogenous apolipoprotein E modulates cholesterol efflux and cholesteryl ester hydrolysis mediated by high-density lipoprotein-3 and lipid-free apolipoproteins in mouse peritoneal macrophages.

Authors:  C Langer; Y Huang; P Cullen; B Wiesenhütter; R W Mahley; G Assmann; A von Eckardstein
Journal:  J Mol Med (Berl)       Date:  2000       Impact factor: 4.599

2.  Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E.

Authors:  R K Tangirala; D Praticó; G A FitzGerald; S Chun; K Tsukamoto; C Maugeais; D C Usher; E Puré; D J Rader
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

3.  Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice.

Authors:  K Tsukamoto; R K Tangirala; S Chun; D Usher; E Puré; D J Rader
Journal:  Mol Ther       Date:  2000-02       Impact factor: 11.454

4.  Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL.

Authors:  Paul J W H Kappelle; Jan Freark de Boer; Frank G Perton; Wijtske Annema; Rindert de Vries; Robin P F Dullaart; Uwe J F Tietge
Journal:  Eur J Clin Invest       Date:  2011-09-28       Impact factor: 4.686

5.  Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I.

Authors:  U J Tietge; C Maugeais; W Cain; D Grass; J M Glick; F C de Beer; D J Rader
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

6.  Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport.

Authors:  Shigenori Yamamoto; Hiroyuki Tanigawa; Xiaoyu Li; Yohei Komaru; Jeffrey T Billheimer; Daniel J Rader
Journal:  Circulation       Date:  2011-08-22       Impact factor: 29.690

7.  Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo.

Authors:  Ilaria Zanotti; Matteo Pedrelli; Francesco Potì; Grazia Stomeo; Monica Gomaraschi; Laura Calabresi; Franco Bernini
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-10-21       Impact factor: 8.311

8.  Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression.

Authors:  Stephane Potteaux; Emmanuel L Gautier; Susan B Hutchison; Nico van Rooijen; Daniel J Rader; Michael J Thomas; Mary G Sorci-Thomas; Gwendalyn J Randolph
Journal:  J Clin Invest       Date:  2011-04-18       Impact factor: 14.808

9.  Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice.

Authors:  C Maugeais; U J Tietge; K Tsukamoto; J M Glick; D J Rader
Journal:  J Lipid Res       Date:  2000-10       Impact factor: 5.922

10.  Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice.

Authors:  Niels Nijstad; Thomas Gautier; François Briand; Daniel J Rader; Uwe J F Tietge
Journal:  Gastroenterology       Date:  2010-12-04       Impact factor: 22.682

View more
  13 in total

1.  The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects.

Authors:  Armin Mooranian; Rebecca Negrulj; Ryu Takechi; John Mamo; Hesham Al-Sallami; Hani Al-Salami
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

2.  Overexpression and deletion of phospholipid transfer protein reduce HDL mass and cholesterol efflux capacity but not macrophage reverse cholesterol transport.

Authors:  Takashi Kuwano; Xin Bi; Eleonora Cipollari; Tomoyuki Yasuda; William R Lagor; Hannah J Szapary; Junichiro Tohyama; John S Millar; Jeffrey T Billheimer; Nicholas N Lyssenko; Daniel J Rader
Journal:  J Lipid Res       Date:  2017-01-30       Impact factor: 5.922

3.  Nuclear receptors and microRNA-144 coordinately regulate cholesterol efflux.

Authors:  Kasey C Vickers; Daniel J Rader
Journal:  Circ Res       Date:  2013-06-07       Impact factor: 17.367

4.  Cholesterol efflux analyses using stable isotopes and mass spectrometry.

Authors:  Robert J Brown; Fei Shao; Angel Baldán; Carolyn J Albert; David A Ford
Journal:  Anal Biochem       Date:  2012-10-13       Impact factor: 3.365

5.  Differential impact of hepatic deficiency and total body inhibition of MTP on cholesterol metabolism and RCT in mice.

Authors:  Arne Dikkers; Wijtske Annema; Jan Freark de Boer; Jahangir Iqbal; M Mahmood Hussain; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2014-02-07       Impact factor: 5.922

Review 6.  New developments in selective cholesteryl ester uptake.

Authors:  Jason M Meyer; Gregory A Graf; Deneys R van der Westhuyzen
Journal:  Curr Opin Lipidol       Date:  2013-10       Impact factor: 4.776

7.  MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor.

Authors:  Thomas Q de Aguiar Vallim; Elizabeth J Tarling; Tammy Kim; Mete Civelek; Ángel Baldán; Christine Esau; Peter A Edwards
Journal:  Circ Res       Date:  2013-03-21       Impact factor: 17.367

8.  Hepatic Overexpression of Endothelial Lipase Lowers High-Density Lipoprotein but Maintains Reverse Cholesterol Transport in Mice: Role of Scavenger Receptor Class B Type I/ATP-Binding Cassette Transporter A1-Dependent Pathways.

Authors:  Shunichi Takiguchi; Makoto Ayaori; Emi Yakushiji; Takafumi Nishida; Kazuhiro Nakaya; Makoto Sasaki; Maki Iizuka; Harumi Uto-Kondo; Yoshio Terao; Makiko Yogo; Tomohiro Komatsu; Masatsune Ogura; Katsunori Ikewaki
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-05-10       Impact factor: 8.311

9.  Single nucleotide polymorphisms in CETP, SLC46A1, SLC19A1, CD36, BCMO1, APOA5, and ABCA1 are significant predictors of plasma HDL in healthy adults.

Authors:  Andrew J Clifford; Gonzalo Rincon; Janel E Owens; Juan F Medrano; Alanna J Moshfegh; David J Baer; Janet A Novotny
Journal:  Lipids Health Dis       Date:  2013-05-08       Impact factor: 3.876

10.  miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity.

Authors:  Ryan M Allen; Tyler J Marquart; Carolyn J Albert; Frederick J Suchy; David Q-H Wang; Meenakshisundaram Ananthanarayanan; David A Ford; Angel Baldán
Journal:  EMBO Mol Med       Date:  2012-07-05       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.